Sovaldi

E411074

antiviral medication direct-acting antiviral hepatitis C drug

Sovaldi is a breakthrough antiviral medication used to treat chronic hepatitis C by directly inhibiting the virus’s replication.

Try in SPARQL Jump to: Surface forms Disambiguation Statements Elicitation Referenced by

All labels observed (3)

Label	Occurrences
sofosbuvir	2
Sofosbuvir	1
Sovaldi canonical	1

How this entity was disambiguated

This entity first appeared as the object of triple T4050931 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.

NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07

Target entity: Sovaldi
Context triple: [Gilead Sciences, product, Sovaldi]

A. Harvoni
Harvoni is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection.
B. Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
C. Truvada
Truvada is a prescription antiretroviral medication widely used both to treat HIV infection and as pre-exposure prophylaxis (PrEP) to help prevent HIV in high-risk individuals.
D. Descovy
Descovy is a prescription antiretroviral medication from Gilead Sciences used for the treatment and prevention (PrEP) of HIV-1 infection.
E. velpatasvir
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
F. None of above. chosen
G. Unsure - the case is ambiguous/there is not enough information to decide.

NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07

Target entity: Sovaldi
Target entity description: Sovaldi is a breakthrough antiviral medication used to treat chronic hepatitis C by directly inhibiting the virus’s replication.

A. Harvoni
Harvoni is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection.
B. Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
C. Truvada
Truvada is a prescription antiretroviral medication widely used both to treat HIV infection and as pre-exposure prophylaxis (PrEP) to help prevent HIV in high-risk individuals.
D. Descovy
Descovy is a prescription antiretroviral medication from Gilead Sciences used for the treatment and prevention (PrEP) of HIV-1 infection.
E. velpatasvir
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
F. None of above. chosen

Statements (49)

Predicate	Object
instanceOf	antiviral medication ⓘ direct-acting antiviral ⓘ hepatitis C drug ⓘ
approvedBy	Food and Drug Administration ⓘ surface form: U.S. Food and Drug Administration
approvedIn	European Union ⓘ United States of America ⓘ surface form: United States
belongsToClass	nucleotide analog polymerase inhibitors ⓘ
boxedWarning	risk of hepatitis B virus reactivation in coinfected patients ⓘ
commonAdverseEffect	fatigue ⓘ headache ⓘ insomnia ⓘ nausea ⓘ
contraindicatedWith	amiodarone (relative contraindication due to bradycardia risk) ⓘ
developedBy	Gilead Sciences (board member) ⓘ surface form: Gilead Sciences
dosageForm	film-coated tablet ⓘ
eliminationHalfLife	approximately 0.4 hours for sofosbuvir ⓘ approximately 27 hours for main metabolite GS-331007 ⓘ
FDAApprovalDate	2013-12-06 ⓘ
hasActiveIngredient	sofosbuvir ⓘ
hasATCCode	J05AX15 ⓘ
hasBreakthroughDesignation	yes (for certain HCV indications) ⓘ
hasGenericName	Sovaldi self-linksurface differs ⓘ surface form: sofosbuvir
hasMechanismOfAction	NS5B RNA-dependent RNA polymerase inhibition ⓘ
indicatedFor	treatment of chronic hepatitis C in adults ⓘ treatment of chronic hepatitis C in pediatric patients 3 years and older ⓘ
inhibits	HCV NS5B RNA-dependent RNA polymerase ⓘ surface form: HCV NS5B polymerase
isFirstInClass	one of the first highly effective oral DAAs for HCV ⓘ
isProdrugOf	sofosbuvir triphosphate ⓘ
marketedBy	Gilead Sciences (board member) ⓘ surface form: Gilead Sciences
metabolizedTo	GS-461203 (active triphosphate) ⓘ
patentHolder	Gilead Sciences (board member) ⓘ surface form: Gilead Sciences
pregnancyCategoryUS	B ⓘ
requiresMonitoring	HBV coinfection status ⓘ hepatic function ⓘ
routeOfAdministration	oral ⓘ
seriousAdverseEffect	severe bradycardia with amiodarone coadministration ⓘ
takenWithFood	may be taken with or without food ⓘ
treats	chronic hepatitis C virus infection ⓘ hepatitis C genotype 1 ⓘ hepatitis C genotype 2 ⓘ hepatitis C genotype 3 ⓘ hepatitis C genotype 4 ⓘ hepatitis C genotype 5 ⓘ hepatitis C genotype 6 ⓘ
typicalDose	400 mg once daily in adults ⓘ
usedInCombinationWith	daclatasvir ⓘ ledipasvir ⓘ peginterferon alfa ⓘ ribavirin ⓘ

How these facts were elicited

Referenced by (4)

Full triples — surface form annotated when it differs from this entity's canonical label.

Gilead Sciences (board member) → product → Sovaldi ⓘ

subject surface form: Gilead Sciences

velpatasvir → usedWith → Sovaldi ⓘ

subject surface form: Velpatasvir

this entity surface form: Sofosbuvir

Harvoni → hasActiveIngredient → Sovaldi ⓘ

this entity surface form: sofosbuvir

Sovaldi → hasGenericName → Sovaldi self-linksurface differs ⓘ